{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T22:48:12Z","timestamp":1648766892127},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1097\/jcp.0b013e3181a33456","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T12:47:24Z","timestamp":1242910044000},"page":"301-302","source":"Crossref","is-referenced-by-count":2,"title":["Aripiprazole Augmentation for a Patient With Partial Remission of Panic Disorder"],"prefix":"10.1097","volume":"29","author":[{"given":"Tsuyoto","family":"Harada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ishigooka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"suppl 8","key":"R1-20-20210128","first-page":"47","article-title":"Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety.","volume":"59","author":"Ballenger","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"suppl 5","key":"R2-20-20210128","first-page":"1","article-title":"Practice guideline for the treatment of patients with panic disorder. Work Group on Panic Disorder.","volume":"155","year":"1998","journal-title":"Am J Psychiatry"},{"issue":"suppl 4","key":"R3-20-20210128","first-page":"23","article-title":"The pharmacotherapy of panic disorder.","volume":"66","author":"Pollack","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R4-20-20210128","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/archpsyc.1997.01830160021003","article-title":"The cross-national epidemiology of panic disorder.","volume":"54","author":"Weissman","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"R5-20-20210128","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4088\/JCP.v67n0307","article-title":"An open-label trial of risperidone augmentation for refractory anxiety disorders.","volume":"67","author":"Simon","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R6-20-20210128","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/01.jcp.0000195108.01898.17","article-title":"Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial.","volume":"26","author":"Sepede","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"R7-20-20210128","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/da.20050","article-title":"Potential effectiveness and safety of olanzapine in refractory panic disorder.","volume":"21","author":"Hollifield","year":"2005","journal-title":"Depress Anxiety"},{"key":"R8-20-20210128","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1017\/S1092852900010002","article-title":"Ziprasidone as an augmenting agent in the treatment of anxiety-spectrum disorders.","volume":"10","author":"Crane","year":"2005","journal-title":"CNS Spectr"},{"key":"R9-20-20210128","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/sj.npp.1300762","article-title":"The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine.","volume":"30","author":"Marek","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"R10-20-20210128","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00213-003-1425-y","article-title":"A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats.","volume":"167","author":"Overstreet","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"R11-20-20210128","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/01.jcp.0000248620.34541.bc","article-title":"An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder.","volume":"27","author":"Menza","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R12-20-20210128","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4088\/JCP.v66n0107","article-title":"The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients.","volume":"66","author":"Connor","year":"2005","journal-title":"J Clin Psychiatry"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-200906000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:14:04Z","timestamp":1618035244000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-200906000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3181a33456","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}